Meeting
2013 ASCO Annual Meeting
A multipeptide vaccine plus toll-like receptor agonists in melanoma patients, with evaluation of the vaccine site microenvironment and sentinel immunized node (Mel58; NCT01585350).
Authors
Craig L. Slingluff Jr.
University of Virginia School of Medicine, Charlottesville, VA
Craig L. Slingluff Jr., Gina R. Petroni , Kimberly A. Chianese-Bullock , William W. Grosh , Geoffrey R. Weiss
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Immunotherapy
Track
Developmental Therapeutics
Sub Track
Vaccines
Clinical Trial Registration Number
NCT01585350
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS3125)
DOI
10.1200/jco.2013.31.15_suppl.tps3125
Abstract #
TPS3125
Poster Bd #
24D
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Phase I trial to determine safety and immunogenicity of amplivant, a synthetic toll-like receptor 2 ligand, conjugated to two HPV16 E6 synthetic long peptides.
First Author: Frank M. Speetjens
Poster
2019 ASCO Annual Meeting
A phase 1/2a study of GEN-009, a neoantigen vaccine based on autologous peptide immune responses.
First Author: Roger B. Cohen
Poster
2017 ASCO Annual Meeting
A toll-like receptor agonist to drive melanoma regression as a vaccination adjuvant or by direct tumor application.
First Author: Richard Eldon Royal
Poster
2016 ASCO Annual Meeting
Pilot trial of intratumoral (IT) G100, a toll-like receptor-4 (TLR4) agonist, in patients (pts) with Merkel cell carcinoma (MCC): Final clinical results and immunologic effects on the tumor microenvironment (TME).
First Author: Shailender Bhatia